Ir al menú de navegación principal Ir al contenido principal Ir al pie de página del sitio

Relación clínica entre helicobacter pylori y la púrpura trombocitopénica inmune: revisión de tema

Clinical relationship between helicobacter pylori and immune thrombocytopenic purpura: a topic review



Abrir | Descargar

Cómo citar

1.
Jaramillo-Aguilar D, Mosquera Monroy RD, Díaz-Vallejo JA, Cuji Galarza WD. Relación clínica entre helicobacter pylori y la púrpura trombocitopénica inmune: revisión de tema. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):222-39. https://doi.org/10.51643/22562915.716

Descargar cita

Citaciones


Sección
Revisiones

Cómo citar
1.
Jaramillo-Aguilar D, Mosquera Monroy RD, Díaz-Vallejo JA, Cuji Galarza WD. Relación clínica entre helicobacter pylori y la púrpura trombocitopénica inmune: revisión de tema. Rev. colomb. hematol. oncol. [Internet]. 2025 Jun. 27 [cited 2025 Dec. 5];12(1):222-39. https://doi.org/10.51643/22562915.716

Dimensions
PlumX
Licencia
Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.


Damary Jaramillo-Aguilar,

 Médica.


Rubén Darío Mosquera Monroy,

Médico.


Jhony Alejandro Díaz-Vallejo,

Médico, Doctorando en Ciencias Biomédicas. Docente Departamento de Ciencias Básicas, Facultad de Ciencias para la Salud, Universidad de Caldas. Grupo de Investigación en Nutrición, Metabolismo y Seguridad Alimentaria, Manizales, Colombia


Wendy Dayanna Cuji Galarza,

Estudiante de Medicina.


Se realizó una revisión temática acerca de los aspectos fisiopatológicos, características clínicas y diagnóstico que fundamentan la relación entre Helicobacter pylori (HP) y la púrpura trombocitopénica inmune (PTI). Mecanismos como el mimetismo molecular y la modulación de la actividad fagocítica han sido propuestos para explicar esta asociación. El diagnóstico de PTI implica una evaluación detallada que considera la historia clínica y pruebas de laboratorio específicas. A pesar de los avances, persisten desafíos en la comprensión de estos mecanismos y en el desarrollo de tratamientos efectivos y personalizados para los pacientes.


Visitas del artículo 281 | Visitas PDF 234


Descargas

Los datos de descarga todavía no están disponibles.
  1. Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program [Internet]. 2013;2013:276-82. Disponible en: https://doi.org/10.1182/asheducation-2013.1.276 DOI: https://doi.org/10.1182/asheducation-2013.1.276
  2. Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol [Internet]. 2020 Nov;27(6):423-429. Disponible en: https://doi.org/10.1097/MOH.0000000000000612 DOI: https://doi.org/10.1097/MOH.0000000000000612
  3. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol [Internet]. 2009;83(2):83-9. Disponible en: https://doi.org/10.1111/j.1600-0609.2009.01247.x DOI: https://doi.org/10.1111/j.1600-0609.2009.01247.x
  4. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology [Internet]. 2017 Aug;153(2):420-9. Disponible en: https://doi.org/10.1053/j.gastro.2017.04.022 DOI: https://doi.org/10.1053/j.gastro.2017.04.022
  5. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol [Internet]. 2010;149(6):855-64. Disponible en: https://doi.org/10.1111/j.1365-2141.2010.08176.x DOI: https://doi.org/10.1111/j.1365-2141.2010.08176.x
  6. Fischbach W, Malfertheiner P. Helicobacter pylori Infection. Dtsch Arztebl Int [Internet]. 2018;115(25):429-36. Disponible en: https://doi.org/10.3238/arztebl.2018.0429 DOI: https://doi.org/10.3238/arztebl.2018.0429
  7. Ouyang Y, Zhang W, Huang Y, Wang Y, Shao Q, Wu X, et al. Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis. Helicobacter [Internet]. 2021;26(3):e12838. Disponible en: https://doi.org/10.1111/hel.12838 DOI: https://doi.org/10.1111/hel.12838
  8. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev [Internet]. 2000;22(2):283-97. Disponible en: https://doi.org/10.1093/oxfordjournals.epirev.a018040 DOI: https://doi.org/10.1093/oxfordjournals.epirev.a018040
  9. De Korwin JD, Ianiro G, Gibiino G, Gasbarrini A. Helicobacter pylori infection and extragastric diseases in 2017. Helicobacter [Internet]. 2017;22 Suppl 1:e12411. Disponible en: https://doi.org/10.1111/hel.12411 DOI: https://doi.org/10.1111/hel.12411
  10. Pellicano R, Ianiro G, Fagoonee S, Settanni CR, Gasbarrini A. Review: Extragastric diseases and Helicobacter pylori. Helicobacter [Internet]. 2020;25 Suppl 1:e12741. Disponible en: https://doi.org/10.1111/hel.12741 DOI: https://doi.org/10.1111/hel.12741
  11. Qiang L, Hu J, Tian M, Li Y, Ren C, Deng Y, et al. Extracellular vesicles from Helicobacter pylori-infected cells and Helicobacter pylori outer membrane vesicles in atherosclerosis. Helicobacter [Internet]. 2022;27(1):e12877. Disponible en: https://doi.org/10.1111/hel.12877 DOI: https://doi.org/10.1111/hel.12877
  12. Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol [Internet]. 2014;11(4):234-42. Disponible en: https://doi.org/10.1038/nrgastro.2014.32 DOI: https://doi.org/10.1038/nrgastro.2013.243
  13. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet [Internet]. 1998;352(9131):878. Disponible en: https://doi.org/10.1016/S0140-6736(05)60004-9 DOI: https://doi.org/10.1016/S0140-6736(05)60004-9
  14. Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol [Internet]. 2006;84(4):309-15. Disponible en: https://doi.org/10.1532/IJH97.06083 DOI: https://doi.org/10.1532/IJH97.06188
  15. Franchini M, Veneri D. Helicobacter pylori-associated immune thrombocytopenia. Platelets [Internet]. 2006;17(2):71-7. Disponible en: https://doi.org/10.1080/09537100500441214 DOI: https://doi.org/10.1080/09537100500438057
  16. Stasi R, Provan D. Helicobacter pylori and Chronic ITP. Hematology Am Soc Hematol Educ Program [Internet]. 2008:206-11. Disponible en: https://doi.org/10.1182/asheducation-2008.1.206 DOI: https://doi.org/10.1182/asheducation-2008.1.206
  17. Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol [Internet]. 2014;20(3):714-23. PMID: 24574745. Disponible en: https://doi.org/10.3748/wjg.v20.i3.714 DOI: https://doi.org/10.3748/wjg.v20.i3.714
  18. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood [Internet]. 2009;113(11):2386-93. PMID: 19005182. Disponible en: https://doi.org/10.1182/blood-2008-07-162503 DOI: https://doi.org/10.1182/blood-2008-07-162503
  19. Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol [Internet]. 2009;46(1 Suppl 2):S2-S14. Disponible en: https://doi.org/10.1053/j.seminhematol.2008.12.005 DOI: https://doi.org/10.1053/j.seminhematol.2008.12.005
  20. Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, et al. Immune thrombocytopenia-current diagnostics and therapy: recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat [Internet]. 2018;41(Suppl 5):1-30. Disponible en: https://doi.org/10.1159/000492187 DOI: https://doi.org/10.1159/000492187
  21. Aljarad S, Alhamid A, Tarabishi AS, Suliman A, Aljarad Z. The impact of Helicobacter pylori eradication on platelet counts of adult patients with idiopathic thrombocytopenic purpura. BMC Hematol [Internet]. 2018;18:28. Disponible en: https://doi.org/10.1186/s12878-018-0119-y DOI: https://doi.org/10.1186/s12878-018-0119-y
  22. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am [Internet]. 2007;21(4):743-59. Disponible en: https://doi.org/10.1016/j.hoc.2007.06.007 DOI: https://doi.org/10.1016/j.hoc.2007.06.007
  23. Gómez-Luna E, Fernando-Navajas D, Aponte-Mayor G, Betancourt-Buitrago LA. Metodología para la revisión bibliográfica y la gestión de información de temas científicos, a través de su estructuración y sistematización. Dyna [Internet]. 2014;81(184):158-63. Disponible en: https://doi.org/10.15446/dyna.v81n184.37066 DOI: https://doi.org/10.15446/dyna.v81n184.37066
  24. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv [Internet], 2019;3(23):3829-66. Disponible en: https://doi.org/10.1182/bloodadvances.2019000966 DOI: https://doi.org/10.1182/bloodadvances.2019000966
  25. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—The Maastricht V/Florence Consensus Report. Gut [Internet]. 2017;66(1):6-30. Disponible en: https://doi.org/10.1136/gutjnl-2016-312288 DOI: https://doi.org/10.1136/gutjnl-2016-312288
  26. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol [Internet]. 2013;62(2):3-26. Disponible en: https://doi.org/10.4166/kjg.2013.62.2.3 DOI: https://doi.org/10.4166/kjg.2013.62.1.3
  27. Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Int J Hematol [Internet]. 2020;111(3):329-51. Disponible en: https://doi.org/10.1007/s12185-019-02790-z DOI: https://doi.org/10.1007/s12185-019-02790-z
  28. Emillia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood [Internet]. 2001;97(3):812-4. Disponible en: https://doi.org/10.1182/blood.V97.3.812 DOI: https://doi.org/10.1182/blood.V97.3.812
  29. Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol [Internet]. 2002;118(2):584-8. Disponible en: https://doi.org/10.1046/j.1365-2141.2002.03635.x DOI: https://doi.org/10.1046/j.1365-2141.2002.03612.x
  30. Hashino S, Mori A, Suzuki S, et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol [Internet]. 2003;77(2):188-91. Disponible en: https://doi.org/10.1007/BF02983219 DOI: https://doi.org/10.1007/BF02983220
  31. Ando K, Shimamoto T, Tauchi T, et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol [Internet]. 2003;77(3):239-44. Disponible en: https://doi.org/10.1007/BF02983779 DOI: https://doi.org/10.1007/BF02983780
  32. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology [Internet]. 1992;102(3):760-6. Disponible en: https://doi.org/10.1016/0016-5085(92)90152-H DOI: https://doi.org/10.1016/0016-5085(92)90156-S
  33. Abdollahi A, Shoar S, Ghasemi S, Zohreh OY. Is Helicobacter pylori Infection a Risk Factor for Idiopathic Thrombocytopenic Purpura in Children? Ann Afr Med [Internet]. 2015;14(4):177-81. Disponible en: https://doi.org/10.4103/1596-3519.149894 DOI: https://doi.org/10.4103/1596-3519.153357
  34. Rajantie J, Klemola T. Helicobacter pylori and Idiopathic Thrombocytopenic Purpura in Children. Blood. 2003;101(4):1660. Disponible en: https://doi.org/10.1182/sangre-2002-10-3201 DOI: https://doi.org/10.1182/blood-2002-10-3201
  35. Kim CY, Lee EH, Yoon HS. High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up. Yonsei Med J [Internet]. 2016;57(1):127-31. Disponible en: https://doi.org/10.3349/ymj.2016.57.1.127 DOI: https://doi.org/10.3349/ymj.2016.57.1.127
  36. Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol [Internet]. 2005;81(2):162-8. Disponible en: https://doi.org/10.1532/IJH97.04079 DOI: https://doi.org/10.1532/IJH97.04146
  37. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. [Internet] 2002;347(15):1175-86. Disponible en: https://doi.org/10.1056/NEJMra020542 DOI: https://doi.org/10.1056/NEJMra020542
  38. Michel M, Cooper N, Christelle J, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood [Internet]. 2004;103(3):890-6. Disponible en: https://doi.org/10.1182/blood-2003-03-0807 DOI: https://doi.org/10.1182/blood-2003-03-0900
  39. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol [Internet]. 2004;124(1):91-6. Disponible en: https://doi.org/10.1046/j.1365-2141.2004.04735.x DOI: https://doi.org/10.1046/j.1365-2141.2003.04735.x
  40. Jackson S, Beck PL, Pineo GF, Poon MC. Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol [Internet]. 2005;78(2):142-50. Disponible en: https://doi.org/10.1002/ajh.20255 DOI: https://doi.org/10.1002/ajh.20250
  41. Pricop L, et al. Differential modulation of stimulatory and inhibitory Fc receptors on human monocytes by Th1 and Th2 cytokines. J Immunol [Internet]. 2001;166(1):531-7. Disponible en: https://doi.org/10.4049/jimmunol.166.1.531 DOI: https://doi.org/10.4049/jimmunol.166.1.531
  42. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, et al. Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest [Internet]. 2008;118(8):2939-49. Disponible en: https://doi.org/10.1172/JCI34496 DOI: https://doi.org/10.1172/JCI34496
  43. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science [Internet]. 2001;291(5503):484-6 PMID: 11161202. Disponible en: https://doi.org/10.1126/science.291.5503.484. DOI: https://doi.org/10.1126/science.291.5503.484
  44. Liu XG, Ma SH, Sun JZ, Ren J, Shi Y, Sun L, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood [Internet]. 2011;117(6):2061-9. PMID: 21131591. Disponible en: https://doi.org/10.1182/blood-2010-07-295477 DOI: https://doi.org/10.1182/blood-2010-07-295477
  45. Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology [Internet]. 2003;124(7):1846-54. Disponible en: https://doi.org/10.1016/S0016-5085(03)00397-4 DOI: https://doi.org/10.1016/S0016-5085(03)00397-4
  46. Andersson NG, Rossing M, Fager Ferrari M, Gabrielaite M, Leinøe E, Ljung R, et al. Genetic screening of children with suspected inherited bleeding disorders. Haemophilia [Internet]. 2020;26(2):314-24. Disponible en: https://doi.org/10.1111/hae.13921 DOI: https://doi.org/10.1111/hae.13948
  47. Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol [Internet]. 2015;170(2):141-9. Disponible en: https://doi.org/10.1111/bjh.13409 DOI: https://doi.org/10.1111/bjh.13385
  48. Kruse C, Kruse A, DiRaimo J. Immune thrombocytopenia: the patient’s perspective. Ann Blood [Internet]. 2021;6:9. Disponible en: https://doi.org/10.21037/aob-20-35 DOI: https://doi.org/10.21037/aob-20-57
  49. Diraimo J, Kruse C, Lambert MP, Kruse A. Impact of Therapy Choice on Fatigue in Adults with Immune Thrombocytopenia. Blood [Internet]. 2020;136(Suppl 1):19-20. Disponible en: https://doi.org/10.1182/blood-2020-139746 DOI: https://doi.org/10.1182/blood-2020-139746
  50. Arnold DM. Bleeding complications in immune thrombocytopenia. Hematol Am Soc Hematol Educ Program [Internet]. 2015;2015(1):237-42. Disponible en: https://doi.org/10.1182/asheducation-2015.1.237 DOI: https://doi.org/10.1182/asheducation-2015.1.237
  51. Izak M, Bussel J. Management of thrombocytopenia. F1000Prime Rep [Internet]. 2014;6:45. Disponible en: https://doi.org/10.12703/P6-45 DOI: https://doi.org/10.12703/P6-45
  52. Hato T, Shimada N, Kurata Y, Kuwana M, Fujimura K, Kashiwagi H, et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Adv [Internet]. 2020;4(8):1648-55. Disponible en: https://doi.org/10.1182/bloodadvances.2019001319 DOI: https://doi.org/10.1182/bloodadvances.2020001446
  53. van Dijk WEM, Punt MC, van Galen KPM, van Leeuwen J, Lely AT, Schutgens REG. Menstrual problems in chronic immune thrombocytopenia: A monthly challenge - a cohort study and review. Br J Haematol [Internet]. 2022;198(4):753-64. Disponible en: https://doi.org/10.1111/bjh.18336 DOI: https://doi.org/10.1111/bjh.18291
  54. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician [Internet]. 2012;85(6):612-22. Disponible en: https://doi.org/10.1097/TA.0b013e318256deab DOI: https://doi.org/10.1097/TA.0b013e318256deab
  55. Bonaccio M, Di Castelnuovo A, Costanzo S, De Curtis A, Donati MB, Cerletti C, et al. Age- and sex-based ranges of platelet count and cause-specific mortality risk in an adult general population: prospective findings from the Moli-sani study. Platelets [Internet]. 2018;29(3):312-5. Disponible en: https://doi.org/10.1080/09537104.2017.1411584 DOI: https://doi.org/10.1080/09537104.2017.1411584
  56. Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, Chesterman CN, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost [Internet]. 2000;83(3):480-4. Disponible en: https://doi.org/10.1055/s-0037-1613813 DOI: https://doi.org/10.1055/s-0037-1613840
  57. Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood [Internet]. 2017;130(10):1247-58. Disponible en: https://doi.org/10.1182/blood-2016-08-734236 DOI: https://doi.org/10.1182/blood-2017-01-757930
  58. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv [Internet]. 2019;3(22):3780-817. Disponible en: https://doi.org/10.1182/bloodadvances.2019000812 DOI: https://doi.org/10.1182/bloodadvances.2019000812
  59. Eyden B, Yong-Xin R, Dong SX, Liu J, Liu XF. Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases. Blood Sci [Internet]. 2021;3(4):107-12. Disponible en: https://doi.org/10.1136/gutjnl-2016-312288 DOI: https://doi.org/10.1097/BS9.0000000000000093
  60. Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Ther Adv Gastroenterol [Internet]. 2021;14:17562848211064080. Disponible en: https://doi.org/10.1177/17562848211064080 DOI: https://doi.org/10.1177/17562848211064080
  61. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol [Internet]. 2017;112(2):212-39. Disponible en: https://doi.org/10.1038/ajg.2016.563 DOI: https://doi.org/10.1038/ajg.2016.563
  62. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol [Internet]. 2007;102(8):1808-25. Disponible en: https://doi.org/10.1111/j.1572-0241.2007.01393.x DOI: https://doi.org/10.1111/j.1572-0241.2007.01393.x
  63. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev [Internet]. 2013;12:CD008337. Disponible en: https://doi.org/10.1002/14651858.CD008337.pub2 DOI: https://doi.org/10.1002/14651858.CD008337.pub2
  64. Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol [Internet]. 2001;115(3):1002-3. Disponible en: https://doi.org/10.1046/j.1365-2141.2001.03194.x DOI: https://doi.org/10.1046/j.1365-2141.2001.03194.x
  65. M. Michel et al. Autoimmune thrombocytopenic Purpura and Helicobacter pylori infection Archives of internal medicine [Internet]. 2002;162(9) 1033-6. Disponible en: https://doi.org/10.1001/archinte.162.9.1033. DOI: https://doi.org/10.1001/archinte.162.9.1033
  66. Ando T, Tsuzuki T, Mizuno T, et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter [Internet]. 2004;9(5):443-52. Disponible en: https://doi.org/10.1111/j.1083-4389.2004.00261.x. DOI: https://doi.org/10.1111/j.1083-4389.2004.00261.x
  67. Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med [Internet]. 2004;164(17):1904-7. Disponible en: https://doi.org/10.1001/archinte.164.17.1904 DOI: https://doi.org/10.1001/archinte.164.17.1904
  68. Payandeh M, Raeisi D, Sohrabi N, Zare ME, Kansestani AN, Keshavarz N, et al. Poor platelet count response to Helicobacter pylori eradication in patients with severe idiopathic thrombocytopenic purpura. Int J Hematol Oncol Stem Cell Res [Internet]. 2013;7(3):9-14. Disponible en: https://doi.org/10.6091/ijhoscr.2013.7.3.9.
Sistema OJS 3.4.0.7 - Metabiblioteca |